Fatty acid amide hydrolase: An emerging therapeutic target in the endocannabinoid system

Current Opinion in Chemical Biology

Volumn 7, Issue 4, 2003, Pages 469-475

  Cravatt, Benjamin F ^a   Lichtman, Aron H ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ANANDAMIDE; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; DRONABINOL; ENZYME INHIBITOR; FATTY ACID AMIDASE; FATTY ACID AMIDASE INHIBITOR; G PROTEIN COUPLED RECEPTOR; UNCLASSIFIED DRUG; URB 532;

AMINO ACID SEQUENCE; ANALGESIA; ANTIEMETIC ACTIVITY; ANXIETY DISORDER; CATABOLISM; CATALEPSY; COGNITIVE DEFECT; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG RESEARCH; DRUG SCREENING; DRUG SELECTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STRUCTURE; FATTY ACID SYNTHESIS; GENE INACTIVATION; GLAUCOMA; HUMAN; HYPOMOTILITY; HYPOTHERMIA; HYPOTHESIS; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; NAUSEA; NERVOUS SYSTEM; NONHUMAN; PAIN; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIDE EFFECT; SPASTICITY; STRUCTURE ANALYSIS; TRANQUILIZING ACTIVITY; TRANSGENIC MOUSE;

MUS MUSCULUS;

EID: 0042572380     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1367-5931(03)00079-6     Document Type: Review

References (43)

1. Matsuda L.A., Lolait S.J., Brownstein M.J., Young A.C., Bonner T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature. 346:1990;561-564.
2. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
3. Mechoulam R: The pharmacohistory of Cannabis sativa. In Cannabinoids as Therapeutic Agents. Edited by Mechoulam R. Boca Raton, Florida: CRS Press; 1986:1-19.
4. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
5. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., Yamashita A., Waku K. 2-Arachidonylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun. 215:1995;89-97.
6. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., Gopher A., Almog S., Martin B.R., Compton D.R. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds cannabinoid receptors. Biochem Pharmacol. 50:1995;83-90.
7. Fukushima N., Ishii I., Contos J.J., Weiner J.A., Chun J. Lysophospholipid receptors. Annu Rev Pharmacol Toxicol. 41:2001;507-534.
8. Patricelli M.P., Cravatt B.F. Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid amides. Vitam Horm. 62:2001;95-131.
9. Sugiura T., Waku K. 2-Arachidonoylglycerol and the cannabinoid receptors. Chem Phys Lipids. 108:2000;89-106.
10. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
11. Jaggar S.I., Hasnie F.S., Sellaturay S., Rice A.S. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 76:1998;189-199.
12. Rodriguez de Fonseca F., Navarro M., Gomez R., Escuredo L., Nava F., Fu J., Murillo-Rodriguez E., Giuffrida A., LoVerme J., Gaetani S.et al. An anorexic lipid mediator regulated by feeding. Nature. 414:2001;209-212.
13. Cravatt B.F., Prospero-Garcia O., Siuzdak G., Gilula N.B., Henriksen S.J., Boger D.L., Lerner R.A. Chemical characterization of a family of brain lipids that induce sleep. Science. 268:1995;1506-1509.
14. Dinh T.P., Freund T.F., Piomelli D. A role for monoacylglyceride lipase in 2-arachidonoylglycerol inactivation. Chem Phys Lipids. 121:2002;149-158.
15. Sugiura T., Kobayashi Y., Oka S., Waku K. Biosynthesis and degradation of anandamide and 2-arachidonoylglycerol and their possible physiological significance. Prostaglandins Leuko Essent Fatty Acids. 66:2002;173-192.
16. Natarajan V., Schmid P.C., Reddy P.V., Zuzarte-Augustin M.L., Schmid H.H. Biosynthesis of N-acylethanolamine phospholipids in dog brain preparations. J Neurochem. 41:1983;1303-1312.
17. Natarajan V., Schmid P.C., Reddy P.V., Schmid H.H. Catabolism of N-acylethanolamine phospholipids by dog brain preparations. J Neurochem. 42:1984;1613-1619.
18. Schmid P.C., Zuzarte-Augustin M.L., Schmid H.H. Properties of rat liver N-acylethanolamine amidohydrolase. J Biol Chem. 260:1985;14145-14149.
19. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem Pharmacol. 46:1993;791-796.
20. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:1996;83-87.
21. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
22. Kumar R.N., Chambers W.A., Pertwee R.G. Pharmacological actions and therapeutic uses of cannabis and cannabinoids. Anaesthesia. 56:2001;1059-1068 An excellent review that highlights the potential therapeutic indications for cannabinoids, as well as the adverse effects of these agents that limit their clinical utility.
23. Breivogel C.S., Childers S.R. The functional neuroanatomy of brain cannabinoid receptors. Neurobiol Dis. 5:1998;417-431.
24. Adams I.B., Compton D.R., Martin B.R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther. 284:1998;1209-1217.
25. Willoughby K.A., Moore S.F., Martin B.R., Ellis E.F. The biodisposition and metabolism of anandamide in mice. J Pharmacol Exp Ther. 282:1997;243-247.
26. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci USA. 98:2001;9371-9376 This paper describes the generation and initial characterization of FAAH-KO mice. These animals were found to show exaggerated behavioural responses to anandamide and highly elevated endogenous brain levels of this FAA that correlated with enhanced CB1-dependent analgesia. These results provide the first direct evidence that FAAH is a primary regulator of anandamide signaling in vivo.
27. Lichtman A.H., Hawkins E.G., Griffin G., Cravatt B.F. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J Pharmacol Exp Ther. 302:2002;73-79.
28. Clement A.C., Hawkins E.G., Lichtman A.H., Cravatt B.F. Increased seizure susceptibility and pro-convulsant activity of anandamide in mice lacking fatty acid amide hydrolase. J Neurosci. 23:2003;3916-3923.
29. Patterson J.E., Ollman I.R., Cravatt B.F., Boger D.L., Wong C.H., Lerner R.A. Inhibition of oleamide hydrolase catalyzed hydrolysis of the endogenous sleep-inducing lipid cis-9-octadecenamide. J Am Chem Soc. 118:1996;5938-5945.
30. ••].
31. Deutsch D.G., Lin S., Hill W.A., Morse K.L., Salehani D., Arreaza G., Omeir R.L., Makriyannis A. Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun. 231:1997;217-221.
32. Deutsch D.G., Omir R., Arreaza G., Salehani D., Prestwich G.D., Huang Z., Howlett A. Methyl arachidonyl fluorophosphonate: a potent irreversible inhibitor of anandamide amidase. Biochem Pharmacol. 53:1997;255-260.
33. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., Mor M., Tarzia G., La Rana G., Calignano A.et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med. 9:2003;76-81 This paper describes the first study of the in vivo effects of FAAH inhibitors. A novel series of carbamate inhibitors was found to augment endogenous brain anandamide levels and produce analgesic and anxiolytic effects in rodents. These findings suggest that FAAH may represent an attractive drug target for the treatment of pain and neuropyschiatric disorders.
34. Sit SY, Xie K: Bisarylimidazolyl fatty acid amide hydrolase inhibitors. Patent application W0 02/087569, 2002.
35. Zimmerman M. Pathobiology of neuropathic pain. Eur J Pharmacol. 429:2001;23-37.
36. Rowland R.S. Using X-ray crystallography in drug discovery. Curr Opin Drug Discov Dev. 5:2002;613-619.
37. Bracey M.H., Hanson M.A., Masuda K.R., Stevens R.C., Cravatt B.F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science. 298:2002;1793-1796 This paper reports the crystal structure of FAAH in complex with an active-site-directed inhibitor. Several unusual structural features of FAAH were noted, including a striking collection of channels that may grant the enzyme simultaneous access to both the membrane and cytoplasmic compartments of the cell. These channels may represent novel sites for inhibitor design.
38. Patricelli M.P., Lovato M.A., Cravatt B.F. Chemical and mutagenic investigations of fatty acid amide hydrolase: evidence for a family of serine hydrolase with distinct catalytic features. Biochemistry. 38:1999;9804-9812.
39. Patricelli M.P., Cravatt B.F. Fatty acid amide hydrolase competitively degrades bioactive amides and esters through a nonconventional catalytic mechanism. Biochemistry. 38:1999;14125-14130.
40. Leung D., Hardouin C., Boger D.L., Cravatt B.F. Discovering potent and selective inhibitors of enzymes in complex proteomes. Nat Biotechnol. 21:2003;687-691 This paper describes a chemical profiling strategy to evaluate the potency and selectivity of enzyme inhibitors directly in whole proteomes. A panel of FAAH inhibitors was screened against multiple mouse tissue proteomes, and selective inhibitors of FAAH were distinguished from structurally similar compounds that exhibit poor selectivity.
41. Sipe J.C., Chiang K., Gerber A.L., Beutler E., Cravatt B.F. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc Natl Acad Sci USA. 99:2002;8394-8399.
42. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science. 296:2002;678-682.
43. Gainetdinov R.R., Caron M.G. Monoamine transporter pharmacology and mutant mice. Trends Pharmacol Sci. 23:2002;367-373.